Protagonist Therapeutics, Inc. (PTGX)

Today's Latest Price: $18.95 USD

0.46 (2.49%)

Updated Oct 30 4:00pm

Add PTGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Protagonist Therapeutics Inc (PTGX) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering PTGX.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
4 $37 $27 $31.75 $18.49 71.71%

PTGX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 4 0 0 0 0 4

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for PTGX as an investment opportunity.

  • The percent of analysts bearish on the stock of PTGX is less than nearly 100% of all US stocks.
  • PTGX has a higher percentage of analysts bullish on the stock than 84.03% of all US stocks.
  • PTGX has a higher average analyst price target than 77.29% of stocks in the small market cap category.
  • Protagonist Therapeutics Inc's upside potential (average analyst target price relative to current price) is higher than 75.71% of all US stocks.
  • Protagonist Therapeutics Inc's variance in analysts' estimates is less than 67.44% of Pharmaceutical Products stocks.
  • The number of analysts covering the stock of PTGX is greater than 33.53% of Pharmaceutical Products stocks.
  • Protagonist Therapeutics Inc's change in bullishness amongst analysts is less than nearly 100% of all US stocks.

Stocks similar to Protagonist Therapeutics Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CRNX, OXFD and DRRX.

What is the outlook for PTGX? Use POWR Ratings for clearer insight into price direction.



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4984 seconds.